DMACDiaMedica Therapeutics Inc.
$8.01+17% 1Y
$8.01
$5.3352 weeks$9.39
DMAC as reported
- Net income
- −$38M
Net income · +27% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$32M
Free cash flow · +23% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$38M | +27% | Q2 2026 |
| EPS | −$0.64 | n/a | Q4 2021 · 18 quarters behind |
| ROE | −73% | n/a | Q2 2026 |
| ROA | −65% | n/a | Q2 2026 |
| Free cash flow | −$32M | +23% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
DiaMedica Therapeutics Inc. (DMAC) · Net incomeNet incomeDiaMedica Therapeutics Inc. (DMAC)